EMA Authorised: Cystadrops (mercaptamine hydrochloride) — Recordati Rare Diseases

View source ↗

Summary

EMA authorised Cystadrops, an eye drop containing mercaptamine hydrochloride, for the treatment of cystinosis; it carries orphan medicine status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis

Drugs mentioned

• Cystadrops (mercaptamine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Cystinosis. MAH: Recordati Rare Diseases. Decision date: 06/06/2025. Orphan medicine